CA-ALORICA
4.3.2024 10:01:32 CET | Business Wire | Press release
Alorica Inc., a global customer experience (CX) leader, announced today the launch of its Real-time Voice Language Translation (ReVoLT), effectively eliminating language barriers during live customer interactions. This offering is the centrepiece of Alorica Clear, an AI-powered solution suite that revolutionises how businesses communicate with their global customer base through seamless voice language translation, accent localisation and background noise cancellation. The services are enabled by an exclusive linguistic processing platform that applies AI to offer translation capabilities designed for multilingual CX across digital and voice channels.
As companies personalise and localise their customer experiences, they face language barriers and cultural nuances that complicate operations and challenge ROI. ReVoLT removes these pain points by providing real-time, bi-directional voice translation in 75 languages. By integrating this technology, organisations can set up their service operations anywhere and support customers across the globe in their native language, improving service and reducing costs by up to 50%.
“The demand for multilingual service is exploding due to an increasingly interconnected world where brands engage consumers through personalised experiences,” stated Mike Clifton, Alorica’s Chief Growth & Transformation Officer. “Customers place high value on localisation, but CX leaders are struggling to efficiently scale their contact centres across multiple geographies. Multilingual support has historically required fragmented queues or locations, which adds complexity and cost while reducing quality. ReVoLT is our strategic response to this growing need, empowering our clients to deliver centralised, effective, and culturally sensitive customer support while achieving significant savings and improved service.”
According to industry data, 29% of businesses cite losing customers because they did not offer multilingual support, and 70% of end users say they feel more loyal to companies that provide services in their native language. Alorica Clear enriches customer interactions and enhances business outcomes through the transformative power of AI, machine translation and large language models.
The Alorica Clear solution suite eliminates friction in global CX delivery through:
- Real-Time Voice Translation – ReVoLT provides bi-directional voice translation, grammar correction and transcription for 75 languages and 200 dialects with high scalability and security.
- Digital Translation – Supporting over 100 languages and dialects, agents can seamlessly deliver multilingual digital transactions via chat, email, and documents.
- Multilingual Cognitive Assistant – Interprets and resolves inquiries digitally in over 100 languages and is uniquely trained to brand voice and objectives.
- Accent Localisation – Mitigates agents' accents during live interactions, adapting to the natural language of the customer to ensure comprehension.
- Noise Cancellation – Eliminates background noise and distractions, tailored to Alorica Anywhere, the company’s work-at-home solution.
“We believe language personalisation is one of the most compelling applications of this exclusive technology, removing longstanding barriers to providing localised service with high quality and efficiency. Real-time voice language translation embodies our commitment to seamless and effective customer experiences, regardless of language differences,” shared Clifton.
Alorica Clear joins the portfolio of technology-infused offerings by Alorica IQ – the company’s digital and innovation practice focused on user experience design, technology solutions and analytics. Experience Alorica Clear’s exclusive Real-Time Voice Language Translation capabilities here.
About Alorica
Alorica creates insanely great digital customer experiences at scale. Our team of 100,000 solutionists, technologists and operators partner with global brands and disruptive innovators to deliver digitally charged, tailored interactions customers crave. With a track record of creating long-term loyalty, Alorica brings actionable insights, proven processes and CX leadership that deliver outcomes critical to clients’ objectives, whether they’re focused on digital optimisation, customer engagement or market expansion. Our digital practice— Alorica IQ—designs, integrates and optimises best-of-breed technology solutions across the customer experience to improve service and increase operational efficiency. Alorica drives CX innovation for the best clients around the globe from its award-winning operations in 19 countries worldwide. To learn more, visit www.alorica.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304683403/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom